The SLC7A11 antibody is a crucial tool for studying the solute carrier family 7 member 11 (SLC7A11) protein, which encodes the xCT subunit of the system Xc− transporter. This antiporter facilitates the exchange of extracellular cystine and intracellular glutamate, playing a key role in maintaining cellular redox balance by supporting glutathione synthesis. Dysregulation of SLC7A11 is linked to oxidative stress management, cancer progression, and ferroptosis resistance. The antibody enables detection and quantification of SLC7A11/xCT expression in various experimental settings, including Western blotting, immunohistochemistry (IHC), and immunofluorescence (IF). Its applications span cancer research, particularly in studying tumor growth, metastasis, and therapeutic resistance, as SLC7A11 is often overexpressed in aggressive cancers. Additionally, it aids in exploring neurodegenerative diseases and ferroptosis-related pathways. Validated antibodies ensure specificity for distinguishing xCT from other SLC family members, providing insights into its role as a potential biomarker or therapeutic target. Researchers rely on this reagent to elucidate mechanisms underlying cellular antioxidant defense, iron metabolism, and drug sensitivity in preclinical models.